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Key Clinical Message
We need to be aware of primary intestinal lymphoproliferative disease (PILD)
associated with ulcerative colitis (UC). We should carefully monitor UC
patients, particularly patients who meet the following conditions; a previous
Epstein-Barr virus infection, treatment duration ≧4 years, male, and age
≧50 years.
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Introduction
There are three main types of drugs that are commonly
used to treat ulcerative colitis (UC): aminosalicylates, cor-
ticosteroids, and immunosuppressants [1, 2]. All drugs
can have unwanted side effects, but some adverse effects
gain little attention in spite of their severity. One such
complication is primary intestinal lymphoproliferative
disease (PILD), which can develop during the treatment
of UC, especially in cases in which the patients are treated
with immunosuppressants [1]. Although UC itself is not
considered to be a risk factor for PILD, UC patients that
are treated with thiopurines are considered to be at a sig-
nificantly high risk of PILD [1, 3–5]. This case raises
issues concerning what we should deal with the risk for
UC treatment-associated PILD.
Case History/Examination
A 69-year-old male had suffered from progressively wors-
ening pain and swelling in his right buttock for 1 month.
The patient had been diagnosed with distal (left-sided)
UC three and a half years ago (Fig. 1). Since then, his UC
had become more extensive over time, resulting in total
colitis requiring triple-drug combination therapy involv-
ing prednisolone (PSL), mesalazine (5-ASA), and azathio-
prine (AZA). At this visit, he had been taking 7.5 mg
PSL, 2 g 5-ASA, and 50 mg AZA daily. The cumulative
dose of PSL and AZA had reached 11,693.5 and
37,250 mg respectively. On inspection, the swelling and
redness affecting his right buttock indicated the presence
of strong inflammation.
Other than the abovementioned conditions, there was
nothing in the patient’s medical, social, or family history
that deserves special mention.
Blood tests revealed a total white blood cell count of
9100/lL and a mildly elevated C-reactive protein level of
10.24 mg/dL.
A contrast-enhanced computed tomography scan
detected partial defects in the rectal wall and a mixture of
gas bubbles and liquid that had spread from the tissues
surrounding the rectum to the subcutaneous tissue, which
were suggestive of necrotizing proctitis and the presence
of a severe perirectal abscess (Fig. 2).
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Differential Diagnosis,
Investigations, and Treatment
It comes down to whether UC had a causal role in the
development of necrotizing proctitis with severe perirectal
abscess; for example, fistula formation or perforated rectal
cancer secondary to UC. Other causes included a variety
of infectious proctitis with a more fulminant course, per-
foration of the rectal cancer unrelated to UC, and so on.
Immediately, the patient underwent emergency surgery
including removal of abscess with necrotic tissue, drain-
age, and ileostomy. In addition to systemic administration
of doripeneme hydrate, the wound left open was managed
by wound cleansing with the use of normal saline squeeze
bottles two times daily.
Outcome and Follow-Up
Daily wound cleansing and the systemic administration of
antibiotics based on antimicrobial susceptibility testing
was continued for about 1 month, but the pelvic infection
remained poorly controlled. We considered that the
underlying cause of the infection was the long-term
administration of corticosteroids and immunosuppres-
sants and that the residual necrotic tissue had become a
breeding ground for bacteria. On day 42 after the emer-
gent surgery, the patient underwent laparoscopy-assisted
total colorectectomy and the removal of the necrotic tis-
sue followed by omentopexy with the aim of controlling
the infection and promoting wound healing in the pelvic
cavity.
A routine histopathological examination of the surgical
specimen (Fig. 3A) confirmed that the UC extended to
the entire colon (Fig. 3B), and surprisingly revealed the
existence of malignant lymphoma in the rectal ulcer. A
further detailed examination identified Epstein-Barr virus-
positive diffuse large B-cell lymphoma (EBV-positive
DLBCL) in the rectum (Fig. 3C). Imaging studies and a
bone marrow biopsy were performed, which did not find
any evidence of pathological lymphadenopathy or bone
marrow infiltration. Therefore, we clinically diagnosed the
(A)
(B)
Figure 1. (A) Colonoscopy performed before admission showed the
mucosal destruction (pseudopolyposis) mainly in the sigmoid colon. (B)
The biopsy specimen obtained from the sigmoid colon as the onset of
ulcerative colitis (UC) shows cryptic distortion and branching, and dense
lymphoplasmacytic with basal plasmacytosis (hematoxylin-eosin staining).
Figure 2. A contrast-enhanced computed tomography scan performed
on admission detected partial defects in the rectal wall and a mixture of
gas bubbles (white arrow) and liquid, which had spread from the tissue
surrounding the rectum to the subcutaneous tissue, which were
suggestive of necrotizing proctitis and the presence of a severe perirectal
abscess (dotted white arrow).
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Figure 3. (A) Total colectectomy specimen. The white arrow indicates the site from where the colonic tissue slices that were subjected to the
histopathological examination shown in (B) were obtained. The dotted white arrow indicates the site from where the rectal tissue slices that were
subjected to the histopathological examination shown in (C) were obtained. (B) The sigmoid colon mucosa apart from the ulcer shows marked
cryptic distortion with Paneth cell metaplasia, thickening of lamina muscularis mucosae, and relatively mild lymphocytic infiltration (compared to
Fig. 1B); findings are consistent with ulcerative colitis in chronic phase. (C) Histologic section of the rectal ulcer demonstrates that there is dense
cellular aggregation in the ulcer edge. High-power view shows that large tumor cells possess irregular-shaped nuclei and scant cytoplasm. Some
nuclei are very large and contain prominent nucleoli, mimicking Hodgkin cells. Immunohistochemically, the tumor cells express CD20, and in situ
hybridization analysis reveals their expression of Epstein-Barr virus encoded RNAs (EBERs).
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patient with EBV-positive DLBCL arising from the rec-
tum and considered that this condition represented a
form of UC associated PILD.
As the infected wound failed to improve despite the
withdrawal of PSL and AZA, a second attempt to remove
the abscess and necrotic tissue followed by drainage was
conducted on day 81 after admission. A histopathological
examination of the granulation tissue surrounding the
necrotic tissue demonstrated proliferating and infiltrating
EBV-positive DLBCL cells (Fig. 4), indicating that the
malignant lymphoma had relapsed locally and that it
might have played a role in prolonging the patient’s infec-
tion.
As the DLBCL had to be treated in order to treat the
infected wound, we started chemotherapy with the R-
THP-CVP regimen (rituximab, therarubicin, cyclophos-
phamide, vindesine, and prednisolone) on day 96 after
admission [6, 7]. However, the first course of chemother-
apy had no effect. The patient became increasingly ill; in
particular, urinary incontinence and lower limb dysesthe-
sia developed and eventually a mixture of urine and
digestive juices drained through the original wound,
which was suggestive of extended tissue destruction due
to the progression of both the malignant lymphoma and
wound infection. The patient died of disseminated intra-
vascular coagulation syndrome secondary to sepsis on day
144 after admission.
Discussion
We experienced a case of primary rectal DLBCL associ-
ated with UC, which had a unique clinical course that
was unlike that of common malignant lymphoma. Gener-
ally, primary gastrointestinal lymphoma decreases the
mechanical strength of the gastrointestinal wall by replac-
ing intestinal tissues as it proliferates, which is considered
to be causally related to perforation [8–10]. In the present
case, the use of steroids (PSL) masked the inflammatory
response that would have been induced when the patient
suffered a rectal perforation, which led to a delay in the
patient seeking medical care and the development of nec-
rotizing proctitis by the time of his visit. Therefore, there
was no choice but to treat the infected wounds as a large
open wound, which made wound management difficult
throughout the patient’s clinical course. A histopathologi-
cal examination of the specimen obtained during the sec-
ond debridement of the open wound showed that
lymphoma cells had spread to the region around the
granulation tissue and had also infiltrated and occluded
some blood vessels. Thus, the locally recurrent lymphoma
not only had a substantially detrimental effect on wound
healing, but also caused further tissue destruction in the
bladder and small intestine, resulting in the leakage of
urine and stool from the open wound.
In this case, three factors, persistent chronic inflamma-
tion due to UC, a previous EBV infection, and the
administration of AZA might have all contributed to the
pathogenesis of the patient’s PILD; that is, primary rectal
DLBCL. Persistent chronic inflammation might play a
role in the promotion of the precursor cells of malignant
lymphoma because it leads to an overstimulated immune
system and the continuous proliferation of immune cells
[11]. In addition, in the presence of over-activated B cells
T cell dysfunction would allow the reactivation of EBV,
which mostly infects B cells [11]. The newly infected and
differentiating B cells would not be controlled by cyto-
toxic T cell responses because of the T cell dysfunction,
which could lead to uncontrolled lymphoproliferation
and the subsequent development of malignant lymphoma
[12, 13]. However, the incidence of PILD among UC
patients is relatively low; that is, less than one in 1500
patients per year, indicating that UC itself is not a signifi-
(A)
(B)
Figure 4. (A) Lymphoma cells diffusely infiltrate the granulation
tissue obtained during the second debridement. (B) Elastica van
Gieson staining reveals their angiocentric feature.
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cant risk factor for PILD [14–16]. In previous reports on
the causal relationship between inflammatory bowel dis-
ease and PILD, the relative risk of PILD associated with
irritable bowel disease (IBD) ranged from 0.4 to 17.51,
suggesting that several reports found no link between the
conditions [3, 4, 16]. On the other hand, UC patients
receiving thiopurines were found to exhibit markedly
increased relative risks of PILD, ranging between 2.97 and
49.52. This indicates that the use of thiopurines in UC
causes an increased risk of PILD [3, 5]. In addition, it has
been reported that in cases of PILD occurring in UC
patients receiving thiopurines more than 90% of them are
EBV-positive on histopathological examination [5, 15].
Form the standpoint of lymphomas, there have been
growing evidence indicating a significant causal relation-
ship between use of thiopurines and development of lym-
phoma [17, 18]. Especially, Khan et al. presented definite
results based on a retrospective, nationwide cohort study
including 4734 UC patients treated with thiopurines for a
median of 1 year [17]. The age-, gender-, and race-
adjusted hazard ratios of developing lymphoma were 4.2
(95% confidence interval, 2.5–6.8; P < 0.0001) while
being treated with thiopurines, and 0.5 (95% confidence
interval, 0.2–1.3; P = 0.17) after discontinuing treatment
with thiopurines compared with unexposed patients. So,
it is extremely important that discontinuing thiopurine
therapy allows for reduction in the risk of lymphoma.
This case report highlights the side effects of drug ther-
apy for UC. Once the cumulative dose of PSL exceeds
10,000 mg, serious side effects, which might be irrevers-
ible, are likely to develop [19]. Therefore, clinicians
should consider surgery before the cumulative dose of
oral corticosteroids reaches this threshold. In the case of
thiopurines, previous studies have produced conflicting
results regarding whether the cumulative dose and/or
duration of AZA are associated with the development of
PILD [3, 20, 21]. However, it should be noted that the
magnitude of overall risk for lymphomas is significantly
associated with therapy duration of 4 years as a threshold
for achieving statistical significance [17, 18]. At this time,
we should not overreact to the risk of PILD development
and stop using thiopurines because they benefit a lot of
UC patients [2], and the incidence of PILD among UC
patients receiving thiopurines is quite low (less than one
in 1000 patients per year) [1]. Since over 90% of adults
have been infected with EBV [22], it is not feasible to
decide whether the use of thiopurines is safe after testing
for the presence or absence of EBV. Instead, the most
practical approach is to monitor UC patients who are
taking thiopurines whilst paying careful attention to the
risk of PILD. In terms of overall risk for lymphomas, the
characteristics of patients requiring special care are as fol-
lows; treatment duration for more than 4 years, male
gender, and age older than 50 or 65 years [17, 18]. On
the other hand, a trial of withdrawal of thiopurine ther-
apy after 3 years may be another option, considering the
results reported by Khan et al. [17].
The outcome of and optimal treatment for UC-associ-
ated PILD are disputed [15, 20, 21, 23, 24] because insuf-
ficient information is available about the condition due to
the limited number of case reports [20]. Therefore, fur-
ther collection and follow-up of reported cases are needed
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